Circulating Tumor DNA to Detect Residual Disease in Breast Cancer

In oncology, the timely detection of residual disease following treatment is paramount for improving clinical outcomes and avoiding unnecessary disease recurrence and progression.

Personalized assays detecting blood-based biomarkers, are enabling the rapid and sensitive detection of residual disease. Thanks to technological advances, these assays are emerging as new options for identifying clinical relapse at earlier timepoints than currently possible in the clinic.

In this webinar you can hear from Medical Oncologist, Pedram Razavi, Memorial Sloan Kettering Cancer Center, as he explores clinical studies highlighting the utility of ctDNA as a biomarker identifying residual disease and recurrence (RDR).

This webinar featured:

  • Fresh insight and data from the MSKCC breast cancer liquid biopsy program
  • Exciting technological advances enabling the utility of non-invasive assays for RDR detection and patient monitoring
  • In depth analysis of the strengths and shortcomings of ctDNA assays
  • Interactive Q&A to ensue you can have your say and get involved in the conversation

About the presenter

Pedram Razavi
Medical Oncologist
Memorial Sloan Kettering Cancer Center

I am a medical oncologist in the Breast Medicine Service and an assistant member of the Scaltriti Lab. My research focuses on circulating tumor DNA as a novel biomarker and genomically driven translational research in breast cancer.

Nitzan Rosenfeld PhD is a world-leader in circulating tumor DNA